Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop M. Kantarjian, Susan O’Brien, Sergernne York et al.|Cancer|2013Cited by 302
ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic LeukemiaElias Jabbour, Hagop Kantarjian, Nicholas J. Short et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 7
A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomesManuel Maroun, Nicholas J. Short, Elias Jabbour et al.|Blood|2025Cited by 2